# TABLE OF CONTENTS

Welcome ......................................................................................................................................................... 3
About MDS ......................................................................................................................................................... 4
Virtual Congress Information ........................................................................................................................................................................................................................ 6
Virtual Congress 2021 Events ........................................................................................................................................................................................................................ 7
CME Information ........................................................................................................................................................................................................................ 8
Session Definitions ........................................................................................................................................................................................................................ 9
Schedule-at-a-Glance ................................................................................................................................................................................................................... 10
Friday, September 17, 2021 ........................................................................................................................................................................................................................ 12
Saturday, September 18, 2021 .................................................................................................................................................................................................................... 12
Sunday, September 19, 2021 ...................................................................................................................................................................................................................... 14
Monday, September 20, 2021 ..................................................................................................................................................................................................................... 20
Tuesday, September 21, 2021 ..................................................................................................................................................................................................................... 25
Wednesday, September 22, 2021 ................................................................................................................................................................................................................30
Thursday, September 23, 2021.................................................................................................................................................................................................................... 32
Non-CME Educational Activities .................................................................................................................................................................................................................. 33
Faculty Listing .................................................................................................................................................................................................................................... 34
Acknowledgements .................................................................................................................................................................................................................................... 37

Click to navigate through program.
Dear Colleagues,

We are excited to share the program of the MDS Virtual Congress 2021 with you. The MDS Leadership, along with the International Congress Oversight Committee, made the decision to host the 2021 International Congress in a primarily virtual format on September 17-22, 2021. We are confident that this decision will help the Society continue to reach all corners of the world and meet the needs of the changing global climate.

MDS has been working on ways to make the Virtual Congress even more successful for 2021 including: high quality movement disorders education, opportunities for post-session discussion, networking opportunities for participants, electronic posters with opportunities to engage with presenters, and an innovative technology platform.

We look forward to virtually welcoming you to the MDS Virtual Congress 2021 in September for no fee (complimentary).

Sincerely,

Claudia Trenkwalder
President, International Parkinson and Movement Disorder Society, 2019-2021

Oscar Gershanik
Chair, International Congress Oversight Committee, 2019-2021

Vincenzo Bonifati
Chair, Congress Scientific Program Committee, 2019-2021
ABOUT MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

PURPOSE, MISSION AND GOALS

Purpose:
The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:
To disseminate knowledge about Movement Disorders by:
• Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
• Sponsoring International Congresses and Symposia on Movement Disorders
• Collaborating with other international organizations and lay groups
• Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:
• Using the Society’s influence and resources to enhance support for research
• Facilitating the dissemination of information about research
• Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:
• Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
• The public (media) and patient support groups by informing them of new research and therapeutic advances
• Governments to assist them in the development of policies that affect support of research and patient care
• Educational efforts to assist in developing standards of training in the specialty

MDS OFFICERS (2019-2021)

President
Claudia Trenkwalder
Germany

President-Elect
Francisco Cardoso
Brazil

Secretary
Bastiaan Bloem
Netherlands

Secretary-Elect
Charles Adler
USA

Treasurer
Louis Tan
Singapore

Treasurer-Elect
Irene Litvan
USA

Past-President
Christopher Goetz
USA

MDS INTERNATIONAL EXECUTIVE COMMITTEE
Shengdi Chen, People’s Republic of China
Mark Edwards, United Kingdom
Cristian Falup-Pecurariu, Romania
Joaquim Ferreira, Portugal
Marina de Koning-Tijssen, Netherlands
Alice Nieuwboer, Belgium
D. James Surmeier, USA
Pille Taba, Estonia
Mayela Rodriguez-Violante, Mexico
Ruey-Meei Wu, Taiwan
ABOUT MDS

INTERNATIONAL CONGRESS OVERSIGHT COMMITTEE

Chair: Oscar Gershanik, Argentina
Vincenzo Bonifati, Netherlands
Francisco Cardoso, Brazil
Christopher Goetz, USA
Tove Henriksen, Denmark
Matthew Stern, USA
Louis Tan, Singapore
Claudia Trenkwalder, Germany

CONGRESS SCIENTIFIC PROGRAM COMMITTEE

Chair: Vincenzo Bonifati, Netherlands
Co-Chair: Tove Henriksen, Denmark
Orlando Barsottini, Brazil
Roongroj Bhidayasiri, Thailand
Per Borghammer, Denmark
Francisco Cardoso, Brazil
Pietro Cortelli, Italy
Terry Ellis, USA
Alberto Espay, USA
Jennifer Friedman, USA
Steven Frucht, USA
Oscar Gershanik, Argentina
Jennifer Goldman, USA
Etienne Hirsch, France
Hyder Jinnah, USA
Beomseok Jeon, South Korea
Andrea Kühn, Germany
Shen-Yang Lim, Malaysia
Karen Marder, USA
Wassilios Meissner, France
Njideka Okubadejo, Nigeria
Tiago Outeiro, Germany
Ron Postuma, Canada
Veronica Santini, USA
Andrew Siderowf, USA
Maria Stamelou, Greece
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Claudia Trenkwalder, Germany

PAST-PRESIDENTS

2017-2019 Christopher Goetz, USA
2015-2017 Oscar Gershanik, Argentina
2013-2015 Matthew Stern, USA
2011-2013 Günther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS

1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS INTERNATIONAL SECRETARIAT

International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
Email: info@movementdisorders.org
Website: www.movementdisorders.org
ABSTRACT POSTER INFORMATION
Beginning on September 10, 2021, Virtual Congress participants can view e-posters in the Poster Hall. Additionally, all abstracts will be published in the Movement Disorders journal e-supplement.

EXHIBITION
Manufacturers, distributors and suppliers of products and services for physicians and researchers involved with Movement Disorders are invited to participate in the Virtual Congress exhibition. To receive a copy of the Exhibitor Prospectus, please visit the International Congress section of the MDS website at https://www.mdscongress.org/Congress/Sponsorship--Exhibiting.htm. The exhibition is open to all registered delegates.

OFFICIAL LANGUAGE
The official language of the MDS Virtual Congress 2021 is English.

REGISTRATION
Registration will open June 7, 2021 for no fee (complimentary) for participants. The MDS Virtual Congress 2021 scientific sessions, sponsored symposia, exhibits and the Poster Hall will be available on demand for free until October 1, 2021. After October 1, 2021, the Virtual Congress will continue to be available on demand for MDS Members for a limited time.

PHOTOGRAPHY AND VIDEO RECORDING POLICY
Photography, video or audio recording (including screen capture) of these sessions, materials, speaker likenesses or MDS graphics without written permission from MDS is strictly prohibited. Please note that photographs and video taken by or on behalf of MDS shall be property of MDS.

Visit the Young Delegate’s Hub
on the Virtual Congress Platform after September 10, 2021 to find resources for career development, network with peers and MDS leadership and to learn about how to get more involved with the Society.

Highlights include:
• On Demand discussions with leaders in the field
• Discussion board to connect with peers
• Ask Me Anything: 30 minute sessions with leaders
• MDS volunteer opportunities
• Upcoming courses of interest to Young Delegates
• MDS membership information
• Photo wall
VIRTUAL CONGRESS 2021 EVENTS

WELCOME CEREMONY
Friday, September 17, 2021
10:00 EDT / 16:00 CEST / 18:00 GST / 23:00 JST

All Virtual Congress delegates are warmly invited to attend the Welcome Ceremony. MDS President Claudia Trenkwalder and other MDS leaders will introduce this event and give a preview of what to expect throughout the meeting.

In celebration of achievements of leaders in the field of Movement Disorders, awards will also be presented during the Welcome Ceremony.

MDS BUSINESS MEETING
Saturday, September 18, 2021
8:00 EDT / 14:00 CEST / 16:00 GST / 21:00 JST

Open to all International Congress delegates, the Society encourages Members to attend the MDS Business Meeting to receive updates from the MDS President and other MDS Officers on the Society and the various Regional Sections, to participate in the Officers’ and International Executive Committee (IEC) election and to discuss other Society activities.

CLOSING REMARKS
Wednesday, September 22, 2021
10:30 EDT / 16:30 CEST / 18:30 GST / 23:30 JST

MDS VIDEO CHALLENGE
Sunday, September 19, 2021
13:00 EDT / 19:00 CEST / 21:00 GST / 2:00 JST (+1)

Eastern Hemisphere Presentation: Monday, September 20, 2021
22:30 EDT / 4:30 CEST / 6:30 GST / 11:30 JST

Please join Masters of Ceremony, Anthony Lang and Kailash Bhatia, as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives of Movement Disorder Centers from around the world. The phenomenology, differential diagnosis and preferential diagnosis will be discussed by an assigned Expert Discussant after which the diagnosis will be revealed. Following this, the highlights and critical learning points/take-home messages will be discussed by one of four Faculty Discussants: Jennifer Friedman, Christine Klein, Manju Kurian and Marina De Koning-Tijssen. Awards will be given for the most interesting and challenging cases. The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

Meet the Experts of the MDS Video Challenge

Faculty Discussants:

Jennifer Friedman, USA
Christine Klein, Germany
Manju Kurian, United Kingdom
Marina De Koning-Tijssen, Netherlands

Expert Discussants:

Zakiyah Aldaajani, Saudi Arabia
Miryam Carecchio, Italy
Silke Appel-Cresswell, Canada
John Duda, USA
Asha Kishore, India
Anna Latorre, United Kingdom
Davide Martino, Canada
Pablo Mir, Spain
Alex Münchau, Germany
Ron Postuma, Canada
TARGET AUDIENCE
This activity is intended for clinicians, researchers, fellows, residents, medical students, and allied health professionals with an interest in current clinical trends and approaches for the diagnosis and treatment of movement disorders.

OBJECTIVES
1. Evaluate the pharmacological and non-pharmacological management options available for Parkinson’s disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders
3. Describe the pathogenesis and neurobiology of Parkinson’s disease and other movement disorders

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 34 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

SATISFACTORY COMPLETION
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit of individual sessions is not available.

CONTENT VALIDITY STATEMENT
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

Network with your colleagues to get the most out of your MDS Virtual Congress 2021 experience.

New this year:
• Meet the Expert Roundtable Discussions
• Post Session Discussions
• Networking Lounge
• Chat Channels

Log in to the Virtual Platform after September 10, 2021 to learn more.
SESSION DEFINITIONS

ACCREDITED SCIENTIFIC SESSIONS

2021 Themed Sessions: At each annual MDS Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme, Towards Personalized Medicine for Movement Disorders, will be showcased with international experts serving as faculty. Meeting participants can elect to attend any or all of these sessions. Themed sessions are designated in the program with 🌐.

Controversies in Movement Disorders: This Plenary Session is designed to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

“Highlights for 2021: Looking Towards 2022” Plenary Session: In this session, MDS experts present compilations of the hottest clinical and basic research articles published in the past year in the whole field of the Movement Disorders, and expected to impact heavily on the future research.

Neuroscience Bridges Plenary Session: In this session, world-renowned neuroscientists provide overviews of their clinical or basic research, on topics of broad interest and relevance for the advancement of knowledge on the nervous system in physiology and pathology.

Parallel Sessions: These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders. All 2021 Parallel Sessions will also feature Top Abstracts.

The Top Abstracts program gives broader visibility to the best original research presented during the MDS Virtual Congress by integrating select high-scoring abstract presentations into the parallel session presentations. Selected Top Abstract authors will present their findings during the session, and participate in the LIVE discussion amongst the session faculty.

Plenary Sessions: These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

Skills Workshops: These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

Special Topics in Movement Disorders: These interactive sessions address “hot” topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

Teaching Courses: These educational programs provide up-to-date information on the clinical and basic science of select topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

Therapeutic Plenary Sessions: These sessions provide an overview of the latest, state-of-the-art options in the diagnosis and management of Parkinson’s disease and other movement disorders.

Video Sessions: These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

NON-ACCREDITED EDUCATIONAL ACTIVITIES AND NETWORKING OPPORTUNITIES

Abstract Presentations: All accepted abstract authors are welcome and encouraged to present their work during the Virtual Congress as a PDF poster and a short oral (video) presentation. Attendees can view abstracts on demand at any time during the Virtual Congress. All accepted abstracts are published by MDS.

Guided Poster Tours: Guided Poster Tours give delegates an opportunity to hear discussion on a select group of high-scoring abstracts dealing with defined topics.

NEW in 2021: Meet the Experts Roundtable Discussions: In an interactive roundtable format, participants of the Meet the Experts Roundtable Discussions will gain practical knowledge from Experts in the field on how to be successful in their careers. Each discussion is limited to a 25-person capacity with advanced sign-up required. More information about the Roundtable Discussions will be available in August.

NEW in 2021: Post-Session Discussions/Networking: Post-Session Discussions offer an opportunity for continued conversation to discuss the learnings and highlights of the session. The discussion will be moderated by Young Members, and will encourage open dialogue and networking amongst all attendees. Session faculty are encouraged to attend, but not required.

Science of Industry Sessions: These interactive sessions will provide attendees with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

SPONSORED SYMPOSIA

Sponsored Symposia: These company-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

MDS VIDEO CHALLENGE

MDS Video Challenge: The goal of this session is for attendees to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide attendees through unique Movement Disorder cases as they are presented by representatives from Movement Disorder centers around the world.

INTERNATIONAL CONGRESS FACULTY ROLES

Chair: Facilitates the learnings of the session, engages the faculty in ongoing discussion with attendees.

CSPC Liaison: Develops the session from the onset; provides guidance to ensure that the learning objectives are met; interacts with Speakers / Presenters to ensure presentations are well integrated and overlap is minimized.

Speaker / Presenter: Creates and delivers the presentation materials, participates in the dialogue of the session.
<table>
<thead>
<tr>
<th>CEST</th>
<th>FRIDAY September 17, 2021</th>
<th>SATURDAY September 18, 2021</th>
<th>SUNDAY September 19, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td>Plenary Session 201: Presidential Lectures Eastern Hemisphere</td>
<td>Therapeutic Plenary Session 101 Eastern Hemisphere</td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>2:00</td>
<td>Non-CME Educational Activities</td>
<td>Post-Session Discussion / Break</td>
<td>Therapeutic Plenary Session 102 Eastern Hemisphere</td>
</tr>
<tr>
<td>2:30</td>
<td>MDS Activities and Events</td>
<td>MDS Business Meeting</td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>3:00</td>
<td>Eastern Hemisphere</td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>3:30</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 103 Eastern Hemisphere</td>
</tr>
<tr>
<td>4:00</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>4:30</td>
<td>Therapeutic Plenary Session 102</td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>5:00</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 104 Eastern Hemisphere</td>
</tr>
<tr>
<td>5:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>6:00</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 101 Eastern Hemisphere</td>
</tr>
<tr>
<td>6:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>6:30</td>
<td></td>
<td></td>
<td>Plenary Session 202 Western Hemisphere</td>
</tr>
<tr>
<td>7:00</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>7:30</td>
<td>Welcome Ceremony</td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>8:00</td>
<td>Therapeutic Plenary Session 102 Western Hemisphere</td>
<td></td>
<td>Parallel Sessions &amp; Teaching Courses</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td>Skills Workshops, Special Topics in Movement Disorders Sessions &amp; Video Sessions</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td>MDS Video Challenge Western Hemisphere</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 103 Western Hemisphere</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 104 Western Hemisphere</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td>Therapeutic Plenary Session 101 Western Hemisphere</td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>14:00</td>
<td>MDS Business Meeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Post-Session Discussion / Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

COLOR KEY

- CME Accredited Sessions
- Non-CME Educational Activities
- MDS Activities and Events
- Breaks
## SCHEDULE-AT-A-GLANCE - Central European Summer Time (CEST), Copenhagen

Participants can view the Schedule-at-a-Glance provided in several different time zones on the [Virtual Congress website](https://www.mdscongress.org).

<table>
<thead>
<tr>
<th>CEST</th>
<th>MONDAY September 20, 2021</th>
<th>TUESDAY September 21, 2021</th>
<th>WEDNESDAY September 22, 2021</th>
<th>THURSDAY September 23, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td>Plenary Session 202 Eastern Hemisphere</td>
<td>Plenary Session 203 Eastern Hemisphere</td>
<td>Plenary Session 205 Eastern Hemisphere</td>
<td>Plenary Session 207 Eastern Hemisphere</td>
</tr>
<tr>
<td>2:00</td>
<td>Plenary Session 202 Eastern Hemisphere</td>
<td>Plenary Session 203 Eastern Hemisphere</td>
<td>Plenary Session 205 Eastern Hemisphere</td>
<td>Plenary Session 207 Eastern Hemisphere</td>
</tr>
<tr>
<td>2:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>3:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>3:30</td>
<td>MDS Video Challenge Eastern Hemisphere</td>
<td>Post-Session Discussion / Break</td>
<td>Post-Session Discussion / Break</td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>4:00</td>
<td>Post-Session Discussion / Break</td>
<td>Post-Session Discussion / Break</td>
<td>Post-Session Discussion / Break</td>
<td>Post-Session Discussion / Break</td>
</tr>
<tr>
<td>4:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>5:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>5:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>6:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>6:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>7:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>7:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>8:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>8:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>9:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>9:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>10:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>10:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>11:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>12:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>12:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>13:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>13:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>14:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>14:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>15:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>16:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>16:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>17:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>17:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>18:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>18:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>19:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>19:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>20:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>20:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>21:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>21:30</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
<tr>
<td>22:00</td>
<td>Plenary Session 204: Neuroscience Bridges Eastern Hemisphere</td>
<td>Plenary Session 206 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
<td>Plenary Session 208 Eastern Hemisphere</td>
</tr>
</tbody>
</table>

**COLOR KEY**
- CME Accredited Sessions
- Non-CME Educational Activities
- MDS Activities and Events
- Breaks
Welcome Ceremony
16:00 CEST – 17:00 CEST

All Virtual Congress delegates are warmly invited to attend the Welcome Ceremony. MDS President Claudia Trenkwalder and other MDS leaders will introduce this event and give a preview of what to expect throughout the meeting.

In celebration of achievements of leaders in the field of Movement Disorders, awards will also be presented during the Welcome Ceremony.

FRIDAY, SEPTEMBER 17, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

201 Plenary Session

Presidential Lectures
2:00 CEST – 3:30 CEST

This session will not feature LIVE question and answer.

Chairs: Francisco Cardoso, Brazil
Claudia Trenkwalder, Germany
C. David Marsden Lecture Award
Etienne Hirsch, France
Stanley Fahn Lecture Award
Oscar Gershanik, Argentina
Junior Award Lecturers
To Be Announced

CSPC Liaisons: Francisco Cardoso, Brazil
Claudia Trenkwalder, Germany

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Summarize the current management strategies for Parkinson’s disease in the early clinical stages
2. Discuss the available management strategies for advanced and complicated Parkinson’s disease
3. Describe the range of non-motor symptoms of Parkinson’s disease and their management

SATURDAY, SEPTEMBER 18, 2021

201 Thematic Plenary Session

Parkinson’s Disease: Early Motor Aspects, Late Motor Aspects, Non-Motor Aspects
12:00 CEST – 14:00 CEST

Chairs: Shen-Yang Lim, Malaysia
Matthew Stern, USA
Early Motor Aspects
Jee-Young Lee, South Korea
Late Motor Aspects
Tove Henriksen, Denmark
Non-Motor Aspects
Maria Cersosimo, Argentina

CSPC Liaisons: Oscar Gershanik, Argentina
Shen-Yang Lim, Malaysia

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Summarize the current management strategies for Parkinson’s disease in the early clinical stages
2. Discuss the available management strategies for advanced and complicated Parkinson’s disease
3. Describe the range of non-motor symptoms of Parkinson’s disease and their management

Symbol Legend:
службав 2021 Themed Session;
суженно This session will feature Post-Session Discussion/Networking;
суженно This session will feature Top Abstract presentations;
суженно To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress
MDS Virtual Congress 2021
SEPTEMBER 17-22

SATURDAY, SEPTEMBER 18, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

Symbol Legend: 2021 Themed Session; This session will feature Post-Session Discussion/Networking; This session will feature Top Abstract presentations; To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress

MDS Business Meeting
14:00 CEST – 15:00 CEST
All participants are encouraged to attend.

102 Therapeutic Plenary Session Diagnosis and Treatment of Atypical Parkinsonism
15:00 CEST – 17:00 CEST
Chairs: Piu Chan, People’s Republic of China
Irene Litvan, USA
Clinical Manifestations and Red-Flag Signs of Atypical Parkinsonism
Han-Joon Kim, South Korea
Imaging and Other Biomarkers in Atypical Parkinsonism
Huw Morris, United Kingdom
Management Strategies for Atypical Parkinsonism
Maria Stamelou, Greece
CSPC Liaisons: Shen-Yang Lim, Malaysia
Wassilios Meissner, France
Recommended Audience: Clinician / General Neurology, Fellow / Resident / Student, Health Professional (non-physician)
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Differentiate atypical parkinsonism based on clinical features
2. Discuss imaging and other biomarkers in atypical parkinsonism
3. Describe management options for atypical parkinsonism

103 Therapeutic Plenary Session Tremor, Dystonia and Ataxia
17:30 CEST – 19:30 CEST
Chairs: Christopher Goetz, USA
Ryuji Kaji, Japan
Diagnosis and Management of Tremor
Peter Bain, United Kingdom
Diagnosis and Management of Dystonia
Joseph Jankovic, USA
Diagnosis and Management of Ataxia
Theresa Zesiewicz, USA
CSPC Liaisons: Buz Jinnah, USA
Maria Stamelou, Greece
Recommended Audience: Clinician / General Neurology, Fellow / Resident / Student, Health Professional (non-physician), Industry, Researcher / Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Describe the diagnosis and management of tremor
2. Describe the diagnosis and management of dystonia
3. Describe the diagnosis and management of ataxia

104 Therapeutic Plenary Session Surgical Interventions for Movement Disorders
20:00 CEST – 22:00 CEST
Chairs: Beomseok Jeon, South Korea
Marie Vidalhiet, France
Deep Brain Stimulation in Parkinson’s Disease: Outcomes and Challenges
Elena Moro, France
Deep Brain Stimulation in Dystonia
Andrea Kühn, Germany
New Imaging Approaches in Deep Brain Stimulation
Michael Fox, USA
CSPC Liaisons: Beomseok Jeon, South Korea
Andrea Kühn, Germany
Recommended Audience: Clinician / General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Discuss the outcomes of current challenges of DBS in the management of Parkinson’s disease
2. Discuss the role of DBS in the management of dystonia
3. Discuss new imaging-based approaches for optimized DBS
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

101 Therapeutic Plenary Session

Parkinson’s Disease: Early Motor Aspects, Late Motor Aspects, Non-Motor Aspects
2:00 CEST – 4:00 CEST

Chairs: Shen-Yang Lim, Malaysia
Matthew Stern, USA
Early Motor Aspects
Jee-Young Lee, South Korea
Late Motor Aspects
Tove Henriksen, Denmark
Non-Motor Aspects
Maria Cersosimo, Argentina

CSPC Liaisons: Oscar Gershankin, Argentina
Shen-Yang Lim, Malaysia

Recommended Audience: Clinician/General Neurology, Fellow/Residents/Student, Health Professional (non-physician), Industry
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Summarize the current management strategies for Parkinson’s disease in the early clinical stages
2. Discuss the available management strategies for advanced and complicated Parkinson’s disease
3. Describe the range of non-motor symptoms of Parkinson’s disease and their management

102 Therapeutic Plenary Session

Diagnosis and Treatment of Atypical Parkinsonism
4:30 CEST – 6:30 CEST

Chairs: Piu Chan, People’s Republic of China
Irene Litvan, USA
Clinical Manifestations and Red-Flag Signs of Atypical Parkinsonism
Han-Joon Kim, South Korea
Imaging and Other Biomarkers in Atypical Parkinsonism
Huw Morris, United Kingdom
Management Strategies for Atypical Parkinsonism
Maria Stamelou, Greece

CSPC Liaisons: Shen-Yang Lim, Malaysia
Wassilios Meissner, France

Recommended Audience: Clinician/General Neurology, Fellow/Residents/Student, Health Professional (non-physician), Industry
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Differentiate atypical parkinsonism based on clinical features
2. Discuss imaging and other biomarkers in atypical parkinsonism
3. Describe management options for atypical parkinsonism

103 Therapeutic Plenary Session

Tremor, Dystonia and Ataxia
7:00 CEST – 9:00 CEST

Chairs: Christopher Goetz, USA
Ryuji Kaji, Japan
Diagnosis and Management of Tremor
Peter Bain, United Kingdom
Diagnosis and Management of Dystonia
Joseph Jankovic, USA
Diagnosis and Management of Ataxia
Theresa Zesiewicz, USA

CSPC Liaisons: Buz Jinnah, USA
Maria Stamelou, Greece

Recommended Audience: Clinician/General Neurology, Fellow/Residents/Student, Health Professional (non-physician), Industry, Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the diagnosis and management of tremor
2. Describe the diagnosis and management of dystonia
3. Describe the diagnosis and management of ataxia

104 Therapeutic Plenary Session

Surgical Interventions for Movement Disorders
9:30 CEST – 11:30 CEST

Chairs: Beomseok Jeon, South Korea
Marie Vidailhet, France
Deep Brain Stimulation in Parkinson’s Disease: Outcomes and Challenges
Elena Moro, France
Deep Brain Stimulation in Dystonia
Andrea Kühn, Germany
New Imaging Approaches in Deep Brain Stimulation
Michael Fox, USA

CSPC Liaisons: Beomseok Jeon, South Korea
Andrea Kühn, Germany

Recommended Audience: Clinician/General Neurology, Fellow/Residents/Student, Health Professional (non-physician), Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Discuss outcomes and current challenges of DBS in the management of Parkinson’s disease
2. Discuss the role of DBS in the management of dystonia
3. Discuss new imaging-based approaches for optimized DBS

Symbol Legend: 2021 Themed Session; ‒ This session will feature Post-Session Discussion/Networking; ≡ This session will feature Top Abstract presentations; 🌊 To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress
SUNDAY, SEPTEMBER 19, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

This session will feature Post-Session Discussion/Networking;
This session will feature Top Abstract presentations;
To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress

Symbol Legend: 🌟 2021 Themed Session; 📚 This session will feature Post-Session Discussion/Networking; 🌟 This session will feature Top Abstract presentations;

To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress

202 Plenary Session 🌟

The Heterogeneity of Parkinson's Disease
12:00 CEST – 14:00 CEST

Chairs: Ron Postuma, Canada
Louis Tan, Singapore

Evolution of Parkinson's Disease Subtypes from Pre-Motor to Late Disease Stages
Michele Hu, United Kingdom

Defining Parkinson's Disease Subtypes According to Their Biomarker Signature
Chin-Hsien Lin, Taiwan

Precision Medicine for Parkinson's Disease Subtypes
Connie Maras, Canada

CSPC Liaisons: Per Borghammer, Denmark
Wassilios Meissner, France

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the evolution of Parkinson's disease subtypes from pre-motor to late disease stages
2. Recognize Parkinson's disease subtypes according to their biomarker signature
3. Discuss precision medicine for Parkinson's disease subtypes

301 Parallel Session 🌟

Treatable Rare Movement Disorders Not to Miss
14:30 CEST – 16:30 CEST

Chairs: Jennifer Friedman, USA
Yoshiki Furukawa, Japan

Metabolic/Genetic Movement Disorders in Childhood
Jeff Waugh, USA

Metabolic/Genetic Movement Disorders in Adulthood
Mayela Rodriguez Violante, Mexico

Autoimmune Movement Disorders
Victor Fung, Australia

CSPC Liaisons: Jennifer Friedman, USA
Maria Stamelou, Greece

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Recognize clinical clues and plan diagnostic workup and management in children with a suspected rare, treatable metabolic/genetic movement disorder
2. Recognize clinical clues and plan diagnostic workup and management in adults with a suspected rare, treatable metabolic/genetic movement disorder
3. Recognize clinical clues and plan diagnostic workup and management in patients with a suspected autoimmune movement disorder

302 Parallel Session 🌟

Targets for Disease Modification in Parkinson's Disease
14:30 CEST – 16:30 CEST

Chairs: Werner Poeewe, Austria
Eduardo Tolosa, Spain

Alpha-synuclein as a Target
Michael Schlossmacher, Canada

Targets Based on Genetic Insights
Valina Dawson, USA

Other Targets
David Devos, France

CSPC Liaisons: Oscar Gershank, Argentina
Andrew Siderowf, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the rationale of targeting alpha-synuclein for disease modification in Parkinson's disease
2. Discuss possible targets for disease modification in Parkinson's disease based on insights from genetics
3. Recognize other putative targets for disease modification in Parkinson's disease

303 Parallel Session 🌟

Functional Movement Disorders: From Neurophysiology to New Management Strategies
14:30 CEST – 16:30 CEST

Chairs: Sarah Lidstone, Canada
Francesca Morgante, United Kingdom

Exploring the Pathophysiology of Functional Movement Disorders
Selma Aybek Rusca, Switzerland

The Role of Multidisciplinary Care and Rehabilitation Therapies
Michele Tinazzi, Italy

Emerging Management Strategies
Kai-Hsiang Chen, Taiwan

CSPC Liaisons: Oscar Gershank, Argentina
Jennifer Goldman, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe the pathophysiology of functional movement disorders studies
2. Discuss the role and evidence base for multidisciplinary and rehabilitation care in the management of functional movement disorders
3. Discuss new management strategies for functional movement disorders

Back to Table of Contents
## SUNDAY, SEPTEMBER 19, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: [https://www.timeanddate.com/worldclock/converter.html](https://www.timeanddate.com/worldclock/converter.html)

### 304 Parallel Session 💫

**Genetics of Parkinson’s Disease: State-of-the-Art and Future Perspectives**  
14:30 CEST – 16:30 CEST

**Chairs:**  
Marcelo Kaufmann, Argentina  
Carolyn Sue, Australia

**Update on the Monogenic Forms of Parkinson’s Disease**  
Andreas Puschmann, Sweden

**Update on the Genome-Wide Association Studies (GWAS) in Parkinson’s Disease**  
Sara Bandres Ciga, USA

**Ongoing and Future Global Collaborative Genetic Studies of Parkinson’s Disease**  
Ignacio Fernandez Mata, USA

**CSPC Liaisons:**  
Vincenzo Bonifati, Netherlands  
Tiago Outeiro, Germany

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science

**Education Level:** Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:  
1. Describe the current landscape of highly-penetrant forms of inherited Parkinson’s disease  
2. Summarize the status of the genome-wide association studies (GWAS) in Parkinson’s disease  
3. Identify the ongoing and future global collaborative efforts in the field of the genetics of Parkinson’s disease

### 305 Parallel Session 💫

**Huntington’s Disease: From Bench to Bedside**  
14:30 CEST – 16:30 CEST

**Chairs:**  
Joaquim Ferreira, Portugal  
Karen Marder, USA

**What’s New in the Genetics of Huntington’s Disease**  
Laura Jardim, Brazil

**The Clinical Continuum from Pre-Manifest to Manifest Huntington’s Disease**  
Julie Stout, Australia

**Present and Future of a Multidisciplinary Approach to Huntington’s Disease Management**  
Anne Rosser, United Kingdom

**CSPC Liaisons:**  
Francisco Cardoso, Brazil  
Karen Marder, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:  
1. Describe the recent developments in the genetics of Huntington’s disease  
2. Describe the clinical features of pre-manifest and manifest Huntington’s disease  
3. Review the multidisciplinary approach to the pharmacological and non-pharmacological management of Huntington’s disease

### 306 Parallel Session 💫

**Update on MRI Imaging in Movement Disorders**  
14:30 CEST – 16:30 CEST

**Chairs:**  
Per Borghammer, Denmark  
Jong-Min Kim, South Korea

**Why Do We Need a Standardized MRI Protocol for Movement Disorders?**  
David Vaillancourt, USA

**Multi-modal MRI in Parkinson’s Disease: More Information, More Knowledge?**  
Sofia Reimao, Portugal

**The Role of MRI in Atypical Parkinsonism: Diagnosis, Prognosis, Progression Markers**  
Stéphane Lehericy, France

**CSPC Liaisons:**  
Roongroj Bhidayasiri, Thailand  
Per Borghammer, Denmark

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:  
1. Explain the need for standardized MRI protocols, which are robust across different imaging centers and MRI platforms  
2. Explain how multi-modal imaging protocols amplify the diagnostic potential of MRI in Parkinson’s disease  
3. Explain how multi-modal MRI can be used for diagnosis, prognostication and as progression markers in atypical Parkinsonism
## SUNDAY, SEPTEMBER 19, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: [https://www.timeanddate.com/worldclock/converter.html](https://www.timeanddate.com/worldclock/converter.html)

<table>
<thead>
<tr>
<th>401 Teaching Course</th>
<th>501 Skills Workshop</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ataxia, Stereotypies, and Myoclonus</strong>&lt;br&gt;14:30 CEST – 16:30 CEST</td>
<td><strong>How to Set Up a Telemedicine Clinic</strong>&lt;br&gt;17:00 CEST – 18:30 CEST</td>
</tr>
<tr>
<td>Chairs: Ritsuko Hanajima, Japan&lt;br&gt;Bart Van De Warrenburg, Netherlands</td>
<td>Jawad Bajwa, Saudi Arabia&lt;br&gt;Asha Kishore, India&lt;br&gt;Meredith Spindler, USA</td>
</tr>
<tr>
<td>Diagnostic Approach to Ataxias&lt;br&gt;Hirohisa Watanabe, Japan</td>
<td>CSPC Liaisons: Roongroj Bhidayasiri, Thailand&lt;br&gt;Alberto Espay, USA</td>
</tr>
<tr>
<td>Stereotypy: The Commonly Missed Movement Disorder&lt;br&gt;Manju Kurian, United Kingdom</td>
<td><strong>Management of Autonomic Disturbances</strong>&lt;br&gt;17:00 CEST – 18:30 CEST</td>
</tr>
<tr>
<td>Diagnosis and Treatment of Myoclonus&lt;br&gt;Samia Ben Sassi, Tunisia</td>
<td>Elizabeth Coon, USA&lt;br&gt;Pietro Guaraldi, Italy</td>
</tr>
<tr>
<td>CSPC Liaisons: Ron Postuma, Canada&lt;br&gt;Carolyn Sue, Australia</td>
<td>CSPC Liaisons: Pietro Cortelli, Italy&lt;br&gt;Veronica Santini, USA</td>
</tr>
<tr>
<td><strong>How to Examine Patients with Movement Disorders</strong>&lt;br&gt;14:30 CEST – 16:30 CEST</td>
<td><strong>How to Become a Successful Movement Disorders Specialist</strong>&lt;br&gt;17:00 CEST – 18:30 CEST</td>
</tr>
<tr>
<td>Chairs: Cynthia Comella, USA&lt;br&gt;Jennifer Friedman, USA</td>
<td>Raymond Rosales, Philippines&lt;br&gt;Kathleen Shannon, USA</td>
</tr>
<tr>
<td>How to Examine Patients with Hypokinetic Movement Disorders&lt;br&gt;Eduardo Tolosa, Spain</td>
<td>CSPC Liaisons: Alberto Espay, USA&lt;br&gt;Oscar Gershank, Argentina</td>
</tr>
<tr>
<td>How to Examine Patients with Hyperkinetic Movement Disorders&lt;br&gt;Susan Bressman, USA</td>
<td>Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student</td>
</tr>
<tr>
<td>How to Examine Pediatric Patients with Movement Disorders&lt;br&gt;Jennifer Friedman, USA</td>
<td>Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert</td>
</tr>
<tr>
<td>CSPC Liaisons: Ron Postuma, Canada&lt;br&gt;Carolyn Sue, Australia</td>
<td>At the conclusion of this session, participants should be better able to:</td>
</tr>
<tr>
<td></td>
<td>1. Recognize the opportunities and challenges of available technology for remote assessment of Parkinson’s disease and other movement disorders</td>
</tr>
<tr>
<td></td>
<td>2. Discuss the steps necessary to implement a telemedicine clinic for patients with movement disorders</td>
</tr>
</tbody>
</table>

**Symbol Legend:** 2021 Themed Session; This session will feature Post-Session Discussion/Networking; This session will feature Top Abstract presentations; To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: [https://www.timeanddate.com/worldclock/converter.html](https://www.timeanddate.com/worldclock/converter.html)

### 602 Special Topics in Movement Disorders

**Exercise in Parkinson’s Disease: Does One Size Fit All?**

17:00 CEST – 18:30 CEST

Daniel Corcos, USA

Alice Nieuwboer, Belgium

**CSPC Liaisons:**

Terry Ellis, USA

Jennifer Goldman, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Assess the evidence for and against a personalized versus generalized approach to exercise prescription in Parkinson’s disease
2. Analyze current evidence to determine optimal dosing of exercise to improve outcomes in Parkinson’s disease

### 603 Special Topics in Movement Disorders

**The Challenges of Parkinson’s Disease in Low and Middle-Income Countries**

17:00 CEST – 18:30 CEST

Gabriel Arango, Colombia

Augustina Charway-Felli, Ghana

**CSPC Liaisons:**

Njideka Okubadejo, Nigeria

Claudia Trenkwalder, Germany

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Describe the challenges of diagnosing and managing Parkinson’s disease in low and middle-income countries
2. Delineate strategies that can improve access to trained healthcare professionals and services for people with Parkinson’s disease in low and middle-income countries

### 604 Special Topics in Movement Disorders

**Emerging Gene and Cell-Based Therapeutic Approaches for Movement Disorders**

17:00 CEST – 18:30 CEST

Pedro Gonzalez-Alegre, USA

Jun Takahashi, Japan

**CSPC Liaisons:**

Vincenzo Bonifati, Netherlands

Carolyn Sue, Australia

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Discuss completed and ongoing clinical trials employing nucleic acids as therapeutic agents for different movement disorders
2. Discuss the different current and future cell-based therapeutic approaches to neurodegenerative movement disorders

### 701 Video Session

**Neuro-Ophthalmology & Movement Disorders**

17:00 CEST – 18:30 CEST

Ji-Soo Kim, South Korea

Janet Rucker, USA

**CSPC Liaisons:**

Orlando Barsottini, Brazil

Shen-Yang Lim, Malaysia

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researchers/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Perform a bedside neuro-ophthalmological examination relevant to movement disorders
2. Describe clinical ocular and eye movement abnormalities that aid diagnosis of common, as well as uncommon, movement disorders
SUNDAY, SEPTEMBER 19, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.
To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

**702 Video Session**

**Pediatric Movement Disorders**
17:00 CEST – 18:30 CEST
Belen Perez Duenas, Spain
Marcelo Masruha, Brazil
CSPC Liaisons: Orlando Barsottini, Brazil
Jennifer Friedman, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician)

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the phenotypic spectrum of movement disorders in children
2. Recognize potentially treatable pediatric movement disorders

**MDS Video Challenge**
19:00 CEST – 22:00 CEST

Please join Masters of Ceremony, Anthony Lang and Kailash Bhatia, as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives of Movement Disorder Centers from around the world. The phenomenology, differential diagnosis and preferential diagnosis will be discussed by an assigned Discussant after which the diagnosis will be revealed. Following this, the highlights and critical learning points/take-home messages will be discussed by one of 4 Experts: Jennifer Friedman, Christine Klein, Manju Kurian and Marina De Koning-Tijssen. Awards will be given for the most interesting and challenging cases. The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.
MONDAY, SEPTEMBER 20, 2021

All Scientific Program sessions will include 30 minutes of Live faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

202 Plenary Session
The Heterogeneity of Parkinson’s Disease
2:00 CEST – 4:00 CEST

Chairs: Ron Postuma, Canada
Louis Tan, Singapore
Michele Hu, United Kingdom
Evolution of Parkinson’s Disease Subtypes from Pre-Motor to Late Disease Stages
Defining Parkinson’s Disease Subtypes According to Their Biomarker Signature
Precision Medicine for Parkinson’s Disease Subtypes
Connie Marros, Canada

CSPC Liaisons: Per Borghammer, Denmark
Wassilios Meissner, France

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science
Education Level: Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the evolution of Parkinson’s disease subtypes from pre-motor to late disease stages
2. Recognize Parkinson’s disease subtypes according to their biomarker signature
3. Discuss precision medicine for Parkinson’s disease subtypes

MDS Video Challenge
4:30 CEST – 7:30 CEST

Please join Masters of Ceremony, Anthony Lang and Kailash Bhatia, as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives of Movement Disorder Centers from around the world. The phenomology, differential diagnosis and preferential diagnosis will be discussed by an assigned Discussant after which the diagnosis will be revealed. Following this, the highlights and critical learning points/take-home messages will be discussed by one of 4 Experts: Jennifer Friedman, Christine Klein, Manju Kurian and Marina De Koning-Tijssen. Awards will be given for the most interesting and challenging cases. The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

203 Plenary Session
Neuro-Infections and Movement Disorders
12:00 CEST – 14:00 CEST

Chairs: Angelo Antonini, Italy
Roongroj Bhidayasiri, Thailand
Neurobiology of SARS-CoV-2
To Be Announced
Movement Disorders in Patients with COVID-19 Infection Cases
Hadi Manji, United Kingdom
Movement Disorders in Chronic Neuroinfections: Phenomenology and Treatment
Pramod Pal, India

CSPC Liaisons: Francisco Cardoso, Brazil
Claudia Trenkwalder, Germany

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Summarize the biology of the SARS-CoV-2 and the pathogenesis of COVID-19 with a focus on the neurological aspects
2. Recognize the neurological phenomenology with a focus on movement disorders in patients with COVID-19
3. Discuss the diagnosis and management of chronic neuroinfections associated with movement disorders

204 Plenary Session
Neuroscience Bridges
14:30 CEST – 16:00 CEST

Chairs: Vincenzo Bonifati, Netherlands
Etienne Hirsch, France
Don Cleveland, USA
Madeline Lancaster, United Kingdom

CSPC Liaisons: Vincenzo Bonifati, Netherlands
Etienne Hirsch, France

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
MONDAY, SEPTEMBER 20, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

307 Parallel Session 🌟 💥
**Glucocerebrosidase (GBA) Variants and Parkinson’s Disease: From Bench to Bedside**
17:00 CEST – 19:00 CEST

Chairs: Ellen Sidransky, USA
Enza Maria Valente, Italy

Molecular Pathogenetic Mechanisms Underlying GBA-associated Parkinson’s Disease
Yoshitaka Nagai, Japan

Clinical Features in GBA-associated Parkinson’s Disease
To Be Announced

Precision Medicine in GBA-associated Parkinson’s Disease
Alice Chen-Plotkin, USA

CSPC Liaisons: Andrew Siderowf, USA
Ryosuke Takahashi, Japan

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science

Education Level: Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the pathogenetic mechanisms in Parkinson’s disease associated with GBA variants
2. Describe the clinical features in Parkinson’s disease associated with GBA variants
3. Discuss precision medicine approaches towards the management of Parkinson’s disease associated with GBA variants

308 Parallel Session ⭐
**Multidisciplinary Care of Movement Disorders via Telehealth**
17:00 CEST – 19:00 CEST

Chairs: Jennifer Goldman, USA
Alice Nieuwboer, Belgium

Models of Multidisciplinary Care via Telehealth: Opportunities and Challenges
Bastiaan Bloem, Netherlands

Delivering Telehealth in Underserved Areas
Njideka Okubadejo, Nigeria

Bringing the Multidisciplinary Rehabilitation Team Together via Telehealth
To Be Announced

CSPC Liaisons: Terry Ellis, USA
Jennifer Goldman, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe multidisciplinary models of telehealth care, and discuss their opportunities and challenges
2. Discuss the delivery of telehealth in underserved areas
3. Discuss the delivery of rehabilitation care through telehealth

309 Parallel Session 🌟
**REM Sleep Behavior Disorder (RBD) and Other Parasomnias in Parkinson’s Disease and Other Synucleinopathies**
17:00 CEST – 19:00 CEST

This session is offered in collaboration with the European Academy of Neurology (EAN).

Chairs: Claudio Bassetti, Switzerland
Claudia Trenkwalder, Germany

Phenomenology
Alejandro Iranzo, Spain

Pathophysiology
Isabelle Arnulf, France

RBD: From Biomarkers to Treatments
Ron Postuma, Canada

CSPC Liaisons: Pietro Cortelli, Italy
Tove Henriksen, Denmark

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician)

Education Level: Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe clinical manifestation of RBD and other parasomnias and their relationships with other clinical entities
2. Describe the pathophysiology and neuropathology underlying RBD and other parasomnias
3. Describe the current status of RBD as a biomarker of synucleinopathies and its management
MONDAY, SEPTEMBER 20, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress.

---

New Approaches and Pitfalls in the Diagnosis and Management of Tourette Syndrome
17:00 CEST – 19:00 CEST

Chairs: Alexander Münchau, Germany
      Tara Murphy, United Kingdom

Pathogenesis of Tourette Syndrome: An Update To Be Announced
Clinical Features Assisting the Differential Diagnosis of Tourette Syndrome
Kirsten Mueller-Vahl, Germany
Medical and Surgical Management of Tourette Syndrome
Tamara Pringsheim, Canada

CSPC Liaisons: Francisco Cardoso, Brazil
              Alberto Espay, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe the diagnostic clues and pathogenesis of Tourette Syndrome
2. Discuss the differential diagnosis of Tourette syndrome
3. Summarize the medical and surgical management of Tourette syndrome

---

The Evolving Spectrum of Movement Disorder Tauopathies
17:00 CEST – 19:00 CEST

Chairs: Charles Adler, USA
       Wassilios Meissner, France

The Phenotypic Spectrum
Melissa Armstrong, USA
Imaging and Other Biomarkers
Yaroslau Compta, Spain
Current Management, Recent and Ongoing Trials
Adam Boxer, USA

CSPC Liaisons: Wassilios Meissner, France
              Maria Stamelou, Greece

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science

Education Level: Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the phenotypic spectrum of movement disorder tauopathies
2. Describe the current evidence on biomarkers for movement disorder tauopathies
3. Describe current and future management in movement disorder tauopathies

---

Dystonia: From Bench to Bedside
17:00 CEST – 19:00 CEST

Chair: Patricia De Carvalho Aguiar, Brazil
       Buz Jinnah, USA

Potential Clinical Implications of Recent Genetic Studies in Dystonia
Michael Zech, Germany
Potential Clinical Implications of Recent Imaging Studies in Dystonia
Kristina Simonyan, USA
Potential Clinical Implications of Recent Pharmacological Studies in Dystonia
Antonio Picani, Italy

CSPC Liaisons: Buz Jinnah, USA
              Maria Stamelou, Greece

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe the clinical implications of recent genetic studies in dystonia
2. Describe the clinical implications of recent neuroimaging studies in dystonia
3. Summarize evidence for potential novel management approaches in dystonia

---

Genetic Testing and Counseling: What Clinicians Need to Know
17:00 CEST – 19:00 CEST

Chair: Rachel Saunders-Pullman, USA
       Susanne Schneider, Germany

Genetic Testing: Techniques and Pitfalls
Andrea Nemeth, United Kingdom
Strategies in Choosing Genetic Tests for Patients with Movement Disorders
Kishore Kumar, Australia
Genetic Counseling in Movement Disorders: Patients and Unaffected Relatives
Deborah Raymond, USA

CSPC Liaisons: Ron Postuma, Canada
              Carolyn Sue, Australia

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Explain the basic concepts of genetic testing and recognize the pitfalls of different genetic testing platforms available
2. Recommend the most appropriate genetic testing platform for patients with movement disorders including considerations for regional differences in genetic testing accessibility
3. Discuss ethical issues and considerations in genetic counseling for patients with movement disorders and their families

Symbol Legend:
MPI 2021 Themed Session;
This session will feature Post-Session Discussion/Networking;
This session will feature Top Abstract presentations;
To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

Symbol Legend: 2021 Themed Session; 👤 This session will feature Post-Session Discussion/Networking; 🌟 This session will feature Top Abstract presentations; ⏳ To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress

### MONDAY, SEPTEMBER 20, 2021

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Chairs</th>
<th>CSPC Liaisons</th>
<th>Recommended Audience</th>
<th>Education Level</th>
<th>At the conclusion of this session, participants should be better able to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>404</td>
<td>Gait Disorders: From Pathophysiology to the Clinic</td>
<td>17:00 CEST – 19:00 CEST</td>
<td>Mark Hallet, USA</td>
<td>Ron Postuma, Canada</td>
<td>Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science</td>
<td>Beginner/Foundational, Intermediate/Experienced, Advanced/Expert</td>
<td>1. Describe the role of different CNS structures in the pathophysiology of gait disorders 2. Recognize the phenomenology of the different gait disorders 3. Diagnose common and rare neurological diseases with prominent gait dysfunction</td>
</tr>
<tr>
<td>504</td>
<td>How to Use the MDS-UPDRS and the MDS-NMS</td>
<td>19:30 CEST – 21:00 CEST</td>
<td>Cristian Falup-Pecurariu, Romania</td>
<td>Nijdeka Okubadejo, Nigeria</td>
<td>Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science</td>
<td>Beginner/Foundational, Intermediate/Experienced</td>
<td>1. Evaluate patients and participants with the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the MDS-Non-motor Rating Scale (MDS-NMS) in clinical and research settings 2. Practice using the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the MDS-Non-motor Rating Scale (MDS-NMS) through interactive exercises and test cases</td>
</tr>
<tr>
<td>503</td>
<td>Speech Disorders in Parkinsonism and Their Management</td>
<td>19:30 CEST – 21:00 CEST</td>
<td>Serge Pinto, France</td>
<td>Terry Ellis, USA</td>
<td>Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science</td>
<td>Beginner/Foundational, Intermediate/Experienced, Advanced/Expert</td>
<td>At the conclusion of this session, participants should be better able to: 1. Distinguish the features and underlying neural correlates of dysarthria in patients with Parkinson’s disease and atypical parkinsonism 2. Describe the role played by PET and SPECT methods in atypical parkinsonism research and in the clinical setting – with emphasis on diagnosis, prog nostication, and progression markers</td>
</tr>
<tr>
<td>605</td>
<td>Nuclear Medicine in the Management of Movement Disorders</td>
<td>19:30 CEST – 21:00 CEST</td>
<td>Nicola Paves, United Kingdom</td>
<td>Per Borghammer, Denmark</td>
<td>Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science</td>
<td>Beginner/Foundational, Intermediate/Experienced</td>
<td>At the conclusion of this session, participants should be better able to: 1. Describe the role played by PET and SPECT methods in Parkinson’s disease research and in the clinical setting – with emphasis on diagnosis, prog nostication, and progression markers 2. Describe the role played by PET and SPECT methods in atypical parkinsonism research and in the clinical setting – with emphasis on diagnosis, prog nostication, and progression markers</td>
</tr>
</tbody>
</table>
### 606 Special Topics in Movement Disorders

**Hereditary Spastic Paraplegia: Clinical Spectrum and Genetic Advances**  
19:30 CEST – 21:00 CEST  
John Fink, USA  
Giovanni Stevanin, France

**CSPC Liaisons:** Jennifer Friedman, USA  
Buz Jinnah, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Discuss the clinical spectrum and approach to diagnosis of hereditary spastic paraplegias  
2. Discuss emerging pathogenetic pathways and implications for the development of rational management strategies for hereditary spastic paraplegias

### 703 Video Session

**A Case Based Approach to Dystonia: What Would You Do?**  
19:30 CEST – 21:00 CEST  
Sun Ju Chung, South Korea  
Francesca Morgante, United Kingdom

**CSPC Liaisons:** Beomseok Jeon, South Korea  
Buz Jinnah, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Recognize unusual presentations of various forms of dystonia  
2. Discuss current options (oral medications, botulinum toxin, Deep Brain Stimulation, rehabilitation) in the management of individual patients with different forms of dystonia

### 607 Special Topics in Movement Disorders

**Health Disparities in Movement Disorders**  
19:30 CEST – 21:00 CEST  
Roland Dominic Jamora, Philippines  
Allison Willis, USA

**CSPC Liaisons:** Nijdeka Okubadejo, Nigeria  
Veronica Santini, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Examine existing racial, gender, and other health disparities in patients with movement disorders  
2. Apply methods to combat health disparities and improve access and quality of movement disorders care

### 704 Video Session

**Neuromodulation in Parkinson’s Disease: A Case-Based Approach**  
19:30 CEST – 21:00 CEST  
Patricia Krause, Germany  
Stephen Tisch, Australia

**CSPC Liaisons:** Beomseok Jeon, South Korea  
Andrea Kühn, Germany

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry

**Education Level:** Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Discuss inclusion and exclusion criteria for Deep Brain Stimulation in Parkinson’s disease  
2. Discuss troubleshooting and parameter setting for optional Deep Brain Stimulation in Parkinson’s disease

### 608 Special Topics in Movement Disorders

**Movement Disorders and Internal Medicine**  
19:30 CEST – 21:00 CEST  
Annu Aggarwal, India  
José Luiz Pedroso, Brazil

**CSPC Liaisons:** Roongroj Bhidayasiri, Thailand  
Buz Jinnah, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician)

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Recognize the phenomenology of the most common movement disorders associated with general medical conditions  
2. Describe the management of common movement disorders associated with general medical conditions

---

**Symbol Legend:**  
- 🌟 2021 Themed Session;  
- 🌟 This session will feature Post-Session Discussion/Networking;  
- 🌟 This session will feature Top Abstract presentations;  
- 🌟 To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress

---

**Back to Table of Contents**

www.mdscongress.org
### 203 Plenary Session
**Infections and Movement Disorders**

**2:00 CEST – 4:00 CEST**

**Chairs:** Angelo Antonini, Italy  
Roongroj Bhidayasiri, Thailand  

**Neurobiology of SARS-CoV-2**
*To Be Announced*

**Movement Disorders in Patients with COVID-19 Infection Cases**
Hadi Manji, United Kingdom

**Movement Disorders in Chronic Neuroinfections: Phenomenology and Treatment**
Pramod Pal, India

**CSPC Liaisons:** Francisco Cardoso, Brazil  
Claudia Trenkwalder, Germany

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

**At the conclusion of this session, participants should be better able to:**
1. Summarize the biology of the SARS-CoV-2 and the pathogenesis of COVID-19 with a focus on the neurological aspects
2. Recognize the neurological phenomenology with a focus on movement disorders in patients with COVID-19
3. Discuss the diagnosis and management of chronic neuroinfections associated with movement disorders

### 204 Plenary Session
**Neuroscience Bridges**

**4:30 CEST – 6:00 CEST**

**This session will not feature LIVE faculty question and answer.**

**Chairs:** Vincenzo Bonifati, Netherlands  
Etienne Hirsch, France  
Don Cleveland, USA  
Madeline Lancaster, United Kingdom

**CSPC Liaisons:** Vincenzo Bonifati, Netherlands  
Etienne Hirsch, France

**Recommended Audience:** Fellow/Resident/Student, Industry, Researcher/Basic Science

**Education Level:** Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe the structures of alpha-synuclein and the relationships with clinical manifestations
2. Discuss the nature and composition of the alpha-synuclein inclusions in the human brain
3. Summarize current knowledge on the mechanisms of alpha-synuclein related neurodegeneration

### 205 Plenary Session
**Update on Alpha-Synuclein Protein: Biology and Pathophysiology**

**12:00 CEST – 14:00 CEST**

**Chairs:** Tiago Outeiro, Germany  
Eng-King Tan, Singapore

**Alpha-synuclein Structures**
Michel Goedert, United Kingdom

**Update on the Lewy Body**
Henning Stahlberg, Switzerland

**Mechanisms of Alpha-synuclein Related Neurodegeneration**
Veerle Baekelandt, Belgium

**CSPC Liaisons:** Per Borghammer, Denmark  
Tiago Outeiro, Germany

**Recommended Audience:** Fellow/Resident/Student, Industry, Researcher/Basic Science

**Education Level:** Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe recent clinical trials for symptomatic control of motor features of Parkinson’s disease
2. Review recent clinical trials for neuropsychiatric and other non-motor features of Parkinson’s disease
3. Discuss recent clinical trials and future prospects for disease modification in Parkinson’s disease

### 206 Plenary Session
**Update on Recent Clinical Trials in Parkinson’s Disease**

**14:30 CEST – 16:30 CEST**

**Chairs:** Olivier Rascol, France  
Yih-Ru Wu, Taiwan  

**Motor Features**
Susan Fox, Canada

**Neuropsychiatric and Other Non-Motor Features**
Simon Lewis, Australia

**Disease Modifications**
Thomas Foltynie, United Kingdom

**CSPC Liaisons:** Wassilios Meissner, France  
Andrew Siderowf, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Discuss recent clinical trials for symptomatic control of motor features of Parkinson's disease
2. Review recent clinical trials for neuropsychiatric and other non-motor features of Parkinson's disease
3. Discuss recent clinical trials and future prospects for disease modification in Parkinson's disease
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

**313 Parallel Session**

**Parkinson’s Disease: Neuroimaging Beyond Dopamine**
17:00 CEST – 19:00 CEST

**Chairs:**
- Marios Politis, United Kingdom
- A. Jon Stoessl, Canada

**Acetylcholine: From Cognitive Functions to Gait?**
- Hitoshi Shimada, Japan

**Serotonin: Motor and Non-Motor Aspects, From Dyskineties to Mood Disorder**
- Heather Wilson, United Kingdom

**Noradrenaline: REM Sleep Behavior Disorder (RBD), Cognition and Other Non-motor Aspects**
- Michael Sommerauer, Denmark

**CSPC Liaisons:**
- Tove Henriksen, Denmark
- Maria Stamelou, Greece

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced

**At the conclusion of this session, participants should be better able to:**
1. Describe the role of the cholinergic systems in the pathophysiology of cognitive and gait disturbances in Parkinson’s disease, and the translational implications
2. Describe the role of the serotonergic systems in the pathophysiology of motor and non-motor aspects of Parkinson’s disease, and the translational implications
3. Describe the role of the noradrenergic systems in the pathophysiology of RBD, cognitive and other non-motor disturbances in Parkinson’s disease, and the translational implications

---

**314 Parallel Session**

**Modifiers of Penetrance in Hereditary Movement Disorders**
17:00 CEST – 19:00 CEST

**Chairs:**
- Caroline Tanner, USA
- Ruey-Mei Wu, Taiwan

**The Genetic Modifiers of Penetrance**
- Ziv Gan-Or, Canada

**The Non-genetic Modifiers of Penetrance**
- Alastair Noyce, United Kingdom

**Reduced Penetrance: Mechanisms and Translational Insights**
- Christine Klein, Germany

**CSPC Liaisons:**
- Vincenzo Bonifati, Netherlands
- Claudia Trenkwalder, Germany

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science

**Education Level:** Intermediate/Experienced, Advanced/Expert

**At the conclusion of this session, participants should be better able to:**
1. Describe the known genetic modifiers of penetrance of inherited movement disorders
2. Describe the known non-genetic modifiers of penetrance of inherited movement disorders
3. Discuss the mechanisms and potential translational implications of reduced penetrance

---

**315 Parallel Session**

**Towards Precision Medicine in Multiple System Atrophy with Revised Diagnostic Criteria**
17:00 CEST – 19:00 CEST

**Chairs:**
- Tetsutaro Ozawa, Japan
- Gregor Wenning, Austria

**Diagnostic Algorithms**
- Horacio Kaufmann, USA

**Personalized Approach to Optimized Care**
- Alessandra Fanciulli, Austria

**Current Status of Disease Modifying Therapies**
- Wolfgang Singer, USA

**CSPC Liaisons:**
- Wassilios Meissner, France
- Veronica Santini, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced

**At the conclusion of this session, participants should be better able to:**
1. Apply a stepwise diagnostic algorithm to patients with suspected multiple system atrophy
2. Create a comprehensive, multidisciplinary, patient-centered care plans, including telemedicine infrastructures
3. Discuss the current status of approaches aimed at disease modification in multiple system atrophy
3. Define cognitive and neuropsychiatric features associated with cerebellar disorders and
2. Describe cognitive and neuropsychiatric impairments associated with dystonia and
1. Identify cognitive and neuropsychiatric features associated with Parkinson’s disease –

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional
CSPC Liaisons: Steven Frucht, Jeremy Schmahmann, USA

318 Parallel Session
Paroxysmal and Episodic Movement Disorders
17:00 CEST – 19:00 CEST

Chairs: Roberto Erro, Italy
Aurelie Meneret, France

Clinical Spectrum, Evaluation and Management
Laura Silva-Moriyama, Brazil

Genetic Etiologies and Biological Mechanisms
Jong Hee Chae, South Korea

Non-Genetic Etiologies and Disease Mechanisms
Russell Dale, Australia

CSPC Liaisons: Buz Jinnah, USA
Maria Stamelou, Greece

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe the clinical spectrum, evaluation and management of intermittent movement disorders, including paroxysmal dyskinesias and episodic ataxias
2. Describe the genetic causes and pathophysiology of intermittent movement disorders, including paroxysmal dyskinesias and episodic ataxias
3. Describe the non-genetic causes and pathophysiology of intermittent movement disorders, including paroxysmal dyskinesias and episodic ataxias

405 Teaching Course
Tremor: Differential Diagnosis and Management
17:00 CEST – 19:00 CEST

Chairs: Günther Deuschl, Germany
Claudia Testa, USA

Clinical and Electrophysiological Approaches to Differential Diagnosis in Tremor
Tabish Saffee, United Kingdom

Pathophysiology of Tremor: Perspectives for Clinical Practice
Ming-Kai Pan, Taiwan

Current and Future Management Options for Tremor
Anhar Hassan, USA

CSPC Liaisons: Ron Postuma, Canada
Carolyn Sue, Australia

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Differentiate the diagnosis of tremor using clinical assessment and electrophysiological studies
2. Discuss the pathophysiology of tremor and the insights for the clinical practice
3. Summarize current and future management options for tremor
TUESDAY, SEPTEMBER 21, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

406 Teaching Course

**Non-Motor Aspects of Parkinson’s Disease**

17:00 CEST – 19:00 CEST

Chairs: Anette Schrag, United Kingdom
Ali Shalash, Egypt

Diagnosis and Management of Bowel and Bladder Dysfunction

Ai Huey Tan, Malaysia

Pain

K. Ray Chaudhuri, United Kingdom

The MDS Non-Motor Rating Scale (MDS-NMS)

Carmen Rodriguez Blazquez, Spain

CSPC Liaisons: Ron Postuma, Canada
Carolyn Sue, Australia

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Describe and manage bowel and bladder dysfunction in Parkinson’s disease
2. Summarize the causes, types, and management of pain in Parkinson’s disease
3. Discuss the characteristics of the MDS Non-motor Rating Scale (MDS-NMS) and its role in the assessment of patients with Parkinson’s disease

506 Skills Workshop

**Device-aided Treatment for Advanced Parkinson’s Disease**

19:30 CEST – 21:00 CEST

Dag Nyholm, Sweden
Onanong Phokaewwarangkul, Thailand

CSPC Liaisons: Tove Henriksen, Denmark
Jennifer Goldman, USA

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician)

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Recognize the different types of device-aided treatments for advanced Parkinson’s disease
2. Discuss the indications and contraindications for each device-aided treatment option

902 Science of Industry (non-CME)

See page page page 33 for complete session information.

505 Skills Workshop

**Botulinum Toxin: A Case-Based Approach**

19:30 CEST – 21:00 CEST

Gonzalo Gomez Arevalo, Argentina
Shivam Mittal, United Arab Emirates

CSPC Liaisons: Roongroj Bhidayasiri, Thailand
Beomseok Jeon, South Korea

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Industry

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Describe optimal strategies for the application of botulinum toxins for hemifacial spasm, cranial dystonia, cervical dystonia, and limb dystonia
2. Describe the optimal strategies for the application of botulinum toxins for the treatment of spasticity affecting the upper and lower limb

609 Special Topics in Movement Disorders

**Lessons From My Patients**

19:30 CEST – 21:00 CEST

Marcelo Merello, Argentina
Huifang Shang, People’s Republic of China

CSPC Liaisons: Tove Henriksen, Denmark
Njideka Okubadejo, Nigeria

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced

At the conclusion of this session, participants should be better able to:
1. Interpret and critique the pertinent historical and examination elements that may be advantageous when diagnosis and management are elusive
2. Identify common pitfalls in the evaluation of movement disorders

610 Special Topics in Movement Disorders

**Unraveling the Role of Autophagy in Parkinsonism: From Bench to Bedside**

19:30 CEST – 21:00 CEST

Hideki Mochizuki, Japan
Maria Xilouri, Greece

CSPC Liaisons: Etienne Hirsch, France
Ryosuke Takahashi, Japan

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Industry, Researcher/Basic Science

Education Level: Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Discuss the mechanisms of autophagy in synucleinopathies and tauopathies
2. Identify the therapeutic potential of modulating autophagy
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

611 Special Topics in Movement Disorders
Non-Invasive Stimulation in Movement Disorders
19:30 CEST – 21:00 CEST
Rubens Gisbert Cury, Brazil
Teresa Kimberley, USA
CSPC Liaisons: Steven Frucht, USA
Andrea Kühn, Germany
Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Researcher/Basic Science
Education Level: Beginner/Foundational, Intermediate/Experienced
At the conclusion of this session, participants should be better able to:
1. Summarize the current knowledge and the potential of non-invasive stimulation as a management modality in movement disorders
2. Describe the current evidence and clinical trials on the effects of non-invasive stimulation in Parkinson’s disease, dystonia, and ataxia

612 Special Topics in Movement Disorders
Metabolic Movement Disorders
19:30 CEST – 21:00 CEST
Serena Galosi, Italy
Fanny Mochel, France
CSPC Liaisons: Jennifer Friedman, USA
Steven Frucht, USA
Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Recognize the phenotypic spectrum of movement disorders caused by metabolic diseases that may present in childhood
2. Recognize the phenotypic spectrum of movement disorders caused by metabolic diseases that may present in adulthood

705 Video Session
Movement Disorders Emergencies
19:30 CEST – 21:00 CEST
Miryam Carecchio, Italy
Thien Thien Lim, Malaysia
CSPC Liaisons: Roongroj Bhidayasiri, Thailand
Shen-Yang Lim, Malaysia
Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician)
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Recognize and discuss management strategies for the various Parkinson’s disease-related, other hypokinetic, and hyperkinetic emergencies
2. Identify movement disorder emergencies related to Deep Brain Stimulation and other device-aided therapies

706 Video Session
Unusual Presentations of Movement Disorders
19:30 CEST – 21:00 CEST
Orlando Barsottini, Brazil
Lucia Ricciardi, United Kingdom
CSPC Liaisons: Orlando Barsottini, Brazil
Alberto Espay, USA
Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student
Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert
At the conclusion of this session, participants should be better able to:
1. Recognize unusual presentation of selected common movement disorders
2. Develop and approach to the expanding phenotypic presentations of movement disorders
All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically.

To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

**Symbol Legend:** 2021 Themed Session; 🌊 This session will feature Post-Session Discussion/Networking; 🌟 This session will feature Top Abstract presentations;

To accommodate participants in both the Western and Eastern Hemispheres, this session will launch twice during the Virtual Congress.

### 205 Plenary Session 🌟

**Update on Alpha-Synuclein Protein: Biology and Pathophysiology**

2:00 CEST – 4:00 CEST

**Chairs:** Tiago Outeiro, Germany
Eng-King Tan, Singapore

**Alpha-synuclein Structures**

Michel Goedert, United Kingdom

**Update on the Lewy Body**

Henning Stahlberg, Switzerland

**Mechanisms of Alpha-synuclein Related Neurodegeneration**

Veerle Baekelandt, Belgium

**CSPC Liaisons:** Per Borghammer, Denmark
Tiago Outeiro, Germany

**Recommended Audience:** Fellow/Resident/Student, Industry, Researcher/Basic Science

**Education Level:** Intermediate/Experienced

At the conclusion of this session, participants should be better able to:

1. Describe the structures of alpha-synuclein and the relationships with clinical manifestations
2. Discuss the nature and composition of the alpha-synuclein inclusion in the human brain
3. Summarize current knowledge on the mechanisms of alpha-synuclein related neurodegeneration

### 206 Plenary Session 🌟

**Update on Recent Clinical Trials in Parkinson’s Disease**

4:30 CEST – 6:30 CEST

**Chairs:** Olivier Rascol, France
Yih-Ru Wu, Taiwan

**Motor Features**

Susan Fox, Canada

**Neuropsychiatric and Other Non-motor Features**

Simon Lewis, Australia

**Disease Modifications**

Thomas Foltynie, United Kingdom

**CSPC Liaisons:** Wassilios Meissner, France
Andrew Siderowf, USA

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Discuss recent clinical trials for symptomatic control of motor features of Parkinson’s disease
2. Review recent clinical trials for neuropsychiatric and other non-motor features of Parkinson’s disease
3. Discuss recent clinical trials and future prospects for disease modification in Parkinson’s disease

### 207 Plenary Session 🌟

**Controversies in Movement Disorders**

12:00 CEST – 14:00 CEST

**Chairs:** Francisco Cardoso, Brazil
Glenda Halliday, Australia

Is clearing of alpha-synuclein aggregates an adequate therapeutic strategy in Parkinson’s disease? (YES)

Patrik Brundin, USA

Is clearing of alpha-synuclein aggregates an adequate therapeutic strategy in Parkinson’s disease? (NO)

Alberto Espay, USA

Should DBS be offered to dystonia patients regardless of etiology? (YES)

Joachim Krauss, Germany

Should DBS be offered to dystonia patients regardless of etiology? (NO)

Marie Vidailhet, France

**CSPC Liaisons:** Vincenzo Bonifati, Netherlands
Francisco Cardoso, Brazil

**Recommended Audience:** Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

**Education Level:** Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:

1. Debate whether clearing of alpha-synuclein aggregates is an adequate therapeutic strategy in Parkinson’s disease
2. Debate whether DBS should be offered to dystonia patients regardless of etiology
WEDNESDAY, SEPTEMBER 22, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

208 Plenary Session

Highlights from 2021: Looking Toward 2022
14:30 CEST – 16:30 CEST

This session will not feature LIVE faculty discussion.

Chairs: Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

Basic Science: Parkinson’s Disease
Tiago Outeiro, Germany

Basic Science: Other Movement Disorders
Per Svenningsson, Sweden

Clinical Studies: Other Movement Disorders
Beomseok Jeon, South Korea

Clinical Studies: Parkinson’s Disease
Steven Frucht, USA

CSPC Liaisons: Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Critically review high-impact scientific discoveries in the field of Movement Disorders published in the past year, and important areas of scientific focus for 2021 and 2022 research.
2. Critically review high-impact clinical studies in the field of Movement Disorders published in the past year, and important ongoing trials with anticipated completion in 2021 and 2022.

Congress Closing Remarks
16:30 CEST – 17:00 CEST

All participants are encouraged to attend.
THURSDAY, SEPTEMBER 23, 2021

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

207 Plenary Session

Controversies in Movement Disorders
2:00 CEST – 4:00 CEST

Chairs: Francisco Cardoso, Brazil
Glenda Halliday, Australia

Is clearing of alpha-synuclein aggregates an adequate therapeutic strategy in Parkinson’s disease? (YES)
Patrik Brundin, USA

Is clearing of alpha-synuclein aggregates an adequate therapeutic strategy in Parkinson’s disease? (NO)
Alberto Espay, USA

Should DBS be offered to dystonia patients regardless of etiology? (YES)
Joachim Krauss, Germany

Should DBS be offered to dystonia patients regardless of etiology? (NO)
Marie Vidalhét, France

CSPC Liaisons: Vincenzo Bonifati, Netherlands
Francisco Cardoso, Brazil

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Debate whether clearing of alpha-synuclein aggregates is an adequate therapeutic strategy in Parkinson’s disease
2. Debate whether DBS should be offered to dystonia patients regardless of etiology

208 Plenary Session

Highlights from 2021: Looking Toward 2022
4:30 CEST – 6:30 CEST

This session will not feature LIVE faculty discussion.

Chairs: Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

Basic Science: Parkinson’s Disease
Tiago Outeiro, Germany

Basic Science: Other Movement Disorders
Per Svenningsson, Sweden

Clinical Studies: Other Movement Disorders
Beomseok Jeon, South Korea

Clinical Studies: Parkinson’s Disease
Steven Frucht, USA

CSPC Liaisons: Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

Recommended Audience: Clinician/General Neurology, Fellow/Resident/Student, Health Professional (non-physician), Industry, Researcher/Basic Science

Education Level: Beginner/Foundational, Intermediate/Experienced, Advanced/Expert

At the conclusion of this session, participants should be better able to:
1. Critically review high-impact scientific discoveries in the field of Movement Disorders published in the past year, and important areas of scientific focus for 2021 and 2022 research
2. Critically review high-impact clinical studies in the field of Movement Disorders published in the past year, and important ongoing trials with anticipated completion in 2021 and 2022
NON-CME EDUCATIONAL ACTIVITIES

All Scientific Program sessions will include 30 minutes of LIVE faculty question and answer unless noted specifically. To verify the session time in your local time zone, please use the following link: https://www.timeanddate.com/worldclock/converter.html

SCIENCE OF INDUSTRY (NON-CME)

These interactive sessions will provide participants with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Monday, September 20, 2021

<table>
<thead>
<tr>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>901</td>
<td>Science of Industry (non-CME) 🌶️🌟</td>
</tr>
</tbody>
</table>

Tuesday, September 21, 2021

<table>
<thead>
<tr>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>902</td>
<td>Science of Industry (non-CME) 🌶️🌟</td>
</tr>
</tbody>
</table>

SPONSORED SYMPOSIA

These company-based informational sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics. Sponsored Symposia will be available on demand for the entirety of the meeting starting Friday, September 17, 2021.

AbbVie Acadia Pharmaceuticals Inc. Allergan, an AbbVie Company BIAL Medtronic Sunovion Pharmaceuticals Inc. Zambon SpA
<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Country</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Adler</td>
<td>USA</td>
<td>312</td>
</tr>
<tr>
<td>Annu Aggarwal</td>
<td>India</td>
<td>608</td>
</tr>
<tr>
<td>Angelo Antonini</td>
<td>Italy</td>
<td>203</td>
</tr>
<tr>
<td>Gabriel Arango</td>
<td>Colombia</td>
<td>603</td>
</tr>
<tr>
<td>Melissa Armstrong</td>
<td>USA</td>
<td>312</td>
</tr>
<tr>
<td>Isabelle Arnulf</td>
<td>France</td>
<td>309</td>
</tr>
<tr>
<td>Selma Aybek Rusca</td>
<td>Switzerland</td>
<td>303</td>
</tr>
<tr>
<td>Veerle Baekelandt</td>
<td>Belgium</td>
<td>205</td>
</tr>
<tr>
<td>Peter Bain</td>
<td>United Kingdom</td>
<td>103</td>
</tr>
<tr>
<td>Jawad Bajwa</td>
<td>Saudi Arabia</td>
<td>501</td>
</tr>
<tr>
<td>Sara Bandres Ciga</td>
<td>USA</td>
<td>304</td>
</tr>
<tr>
<td>Orlando Barsottini</td>
<td>Brazil</td>
<td>706</td>
</tr>
<tr>
<td>Claudio Bassetti</td>
<td>Switzerland</td>
<td>309</td>
</tr>
<tr>
<td>Samia Ben Sasssi</td>
<td>Tunisia</td>
<td>401</td>
</tr>
<tr>
<td>Roongroj Bhidayasiri</td>
<td>Thailand</td>
<td>203</td>
</tr>
<tr>
<td>Bastiaan Bloem</td>
<td>Netherlands</td>
<td>308</td>
</tr>
<tr>
<td>Vincenzo Bonifati</td>
<td>Netherlands</td>
<td>204, 208</td>
</tr>
<tr>
<td>Per Borghammer</td>
<td>Denmark</td>
<td>306</td>
</tr>
<tr>
<td>Adam Boxer</td>
<td>USA</td>
<td>312</td>
</tr>
<tr>
<td>Susan Bressman</td>
<td>USA</td>
<td>402</td>
</tr>
<tr>
<td>Helen Bronte-Stewart</td>
<td>USA</td>
<td>902</td>
</tr>
<tr>
<td>Patrik Brundin</td>
<td>USA</td>
<td>207</td>
</tr>
<tr>
<td>Francisco Cardoso</td>
<td>Brazil</td>
<td>201, 207</td>
</tr>
<tr>
<td>Miryam Carecchio, Italy</td>
<td>Italy</td>
<td>705</td>
</tr>
<tr>
<td>Maria Cerzosimo, Argentina</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Jong Hee Chae, South Korea</td>
<td>318</td>
<td></td>
</tr>
<tr>
<td>Piu Chan, People’s Republic of China</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>Augustina Charway-Felli, Ghana</td>
<td>603</td>
<td></td>
</tr>
<tr>
<td>K. Ray Chaudhuri, United Kingdom</td>
<td>406</td>
<td></td>
</tr>
<tr>
<td>Kai-Hsiang Chen, Taiwan</td>
<td>303</td>
<td></td>
</tr>
<tr>
<td>Alice Chen-Plotkin, USA</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>Sun Ju Chung, South Korea</td>
<td>703</td>
<td></td>
</tr>
<tr>
<td>Don Cleveland, USA</td>
<td>204</td>
<td></td>
</tr>
<tr>
<td>Cynthia Comella, USA</td>
<td>402</td>
<td></td>
</tr>
<tr>
<td>Yaroslau Compta, Spain</td>
<td>312</td>
<td></td>
</tr>
<tr>
<td>Elizabeth Coon, USA</td>
<td>502</td>
<td></td>
</tr>
<tr>
<td>Daniel Corcos, USA</td>
<td>602</td>
<td></td>
</tr>
<tr>
<td>Russell Dale, Australia</td>
<td>318</td>
<td></td>
</tr>
<tr>
<td>Valina Dawson, USA</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>Patricia De Carvalho Aguiari, Brazil</td>
<td>311</td>
<td></td>
</tr>
<tr>
<td>Roberto Erro, Italy</td>
<td>318</td>
<td></td>
</tr>
<tr>
<td>Alberto Espay, USA</td>
<td>207</td>
<td></td>
</tr>
<tr>
<td>Cristian Falup-Pecurariu, Romania</td>
<td>504</td>
<td></td>
</tr>
<tr>
<td>Alessandra Fanciulli, Austria</td>
<td>315</td>
<td></td>
</tr>
<tr>
<td>Alfonso Fasano, Canada</td>
<td>404</td>
<td></td>
</tr>
<tr>
<td>Hubert Fernandez, USA</td>
<td>901</td>
<td></td>
</tr>
<tr>
<td>Ignacio Fernandez Mata, USA</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>Joaquim Ferreira, Portugal</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>John Fink, USA</td>
<td>606</td>
<td></td>
</tr>
<tr>
<td>Thomas Foltynie, United Kingdom</td>
<td>206</td>
<td></td>
</tr>
<tr>
<td>Michael Fox, USA</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>Susan Fox, Canada</td>
<td>206</td>
<td></td>
</tr>
<tr>
<td>Jennifer Friedman, USA</td>
<td>301, 402</td>
<td></td>
</tr>
<tr>
<td>Steven Frucht, USA</td>
<td>208</td>
<td></td>
</tr>
<tr>
<td>Victor Fung, Australia</td>
<td>301</td>
<td></td>
</tr>
<tr>
<td>Yoshiaki Furukawa, Japan</td>
<td>301</td>
<td></td>
</tr>
<tr>
<td>Serena Galosi, Italy</td>
<td>612</td>
<td></td>
</tr>
<tr>
<td>Ziv Gan-Or, Canada</td>
<td>314</td>
<td></td>
</tr>
<tr>
<td>Oscar Gershnik, Argentina</td>
<td>201</td>
<td></td>
</tr>
<tr>
<td>Rubens Gisbert Cury, Brazil</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Michel Goedert, United Kingdom</td>
<td>205</td>
<td></td>
</tr>
<tr>
<td>Christopher Goetz, USA</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td>Jennifer Goldman, USA</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>Gonzalo Gomez Arevalo, Argentina</td>
<td>505</td>
<td></td>
</tr>
<tr>
<td>Pedro Gonzalez-Alegre, USA</td>
<td>604</td>
<td></td>
</tr>
<tr>
<td>Pietro Guaraldi, Italy</td>
<td>502</td>
<td></td>
</tr>
<tr>
<td>Mark Hallett, USA</td>
<td>404</td>
<td></td>
</tr>
<tr>
<td>Glenda Halliday, Australia</td>
<td>207</td>
<td></td>
</tr>
<tr>
<td>Ritsuko Hanajima, Japan</td>
<td>401</td>
<td></td>
</tr>
<tr>
<td>Anhar Hassan, USA</td>
<td>405</td>
<td></td>
</tr>
<tr>
<td>Tove Henriksen, Denmark</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Etienne Hirsch, France</td>
<td>201, 204</td>
<td></td>
</tr>
<tr>
<td>Michele Hu, United Kingdom</td>
<td>202</td>
<td></td>
</tr>
<tr>
<td>Alejandro Iranzo, Spain</td>
<td>309</td>
<td></td>
</tr>
<tr>
<td>Priya Jagota, Thailand</td>
<td>317</td>
<td></td>
</tr>
<tr>
<td>Joseph Jankovic, USA</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td>Laura Jardim, Brazil</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>Beomseok Jeon, South Korea</td>
<td>104, 208</td>
<td></td>
</tr>
<tr>
<td>Buz Jinnah, USA</td>
<td>311</td>
<td></td>
</tr>
<tr>
<td>Ryuji Kaji, Japan</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td>Marcelo Kauffman, Argentina</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>Horacio Kaufmann, USA</td>
<td>315</td>
<td></td>
</tr>
<tr>
<td>Han-Joon Kim, South Korea</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>Jong-Min Kim, South Korea</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>Ji-Soo Kim, South Korea</td>
<td>701</td>
<td></td>
</tr>
<tr>
<td>Teresa Kimberley, USA</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Asha Kishore, India</td>
<td>501</td>
<td></td>
</tr>
<tr>
<td>Christine Klein, Germany</td>
<td>314</td>
<td></td>
</tr>
<tr>
<td>Benzi Kluger, USA</td>
<td>316</td>
<td></td>
</tr>
<tr>
<td>Faculty Listing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patricia Krause, Germany 704</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joachim Krauss, Germany 207</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrea Kühn, Germany 104, 902</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaime Kulisevsky, Spain 317</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kishore Kumar, Australia 403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manju Kurian, United Kingdom 401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madeline Lancaster, United Kingdom 204</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jee-Young Lee, South Korea 101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stéphane Lehericy, France 306</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon Lewis, Australia 206</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarah Lidstone, Canada 303</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shen-Yang Lim, Malaysia 101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thien Thien Lim, Malaysia 705</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chin-Hsien Lin, Taiwan 202</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irene Litvan, USA 102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicholas Maling, USA 902</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hadi Manji, United Kingdom 203</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Marder, USA 305</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connie Marras, Canada 202</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marcelo Masruha, Brazil 702</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Victor McConvey, Australia 316</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wassilios Meissner, France 312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aurelie Meneret, France 318</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marcelo Merello, Argentina 609</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anat Mirelman, Israel 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shivam Mittal, United Arab Emirates 505</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janis Miyasaki, Canada 316</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fanny Mochel, France 612</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hideki Mochizuki, Japan 610</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesca Morgante, United Kingdom 303, 703</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elena Moro, France 104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huw Morris, United Kingdom 102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirsten Mueller-Vahl, Germany 310</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alexander München, Germany 310</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tara Murphy, United Kingdom 310</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoshitaka Nagai, Japan 307</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrea Nemeth, United Kingdom 403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolf-Jürgen Neumann, Germany 902</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alice Nieuwboer, Belgium 308, 602</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alastair Noyce, United Kingdom 314</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dag Nyholm, Sweden 506</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Njideka Okubadejo, Nigeria 308</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiago Outeiro, Germany 205, 208</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetsutarō Ozawa, Japan 315</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pramod Pal, India 203</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ming-Kai Pan, Taiwan 405</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pattamon Panyakaew, Thailand 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicola Pavese, United Kingdom 605</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathryn Peall, United Kingdom 317</td>
<td></td>
<td></td>
</tr>
<tr>
<td>José Luiz Pedroso, Brazil 608</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belen Perez Duenas, Spain 702</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onanong Phokaewvarangkul, Thailand 506</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serge Pinto, France 503</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antonio Pisani, Italy 311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Werner Poewe, Austria 302</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marios Politis, United Kingdom 313</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ron Postuma, Canada 202, 309</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamara Pringsheim, Canada 310</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andreas Puschmann, Sweden 304</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olivier Rascol, France 206</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deborah Raymond, USA 403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sofia Reimao, Portugal 306</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irena Rektorova, Czech Republic 317</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lucia Ricciardi, United Kingdom 706</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lynn Rochester, United Kingdom 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carmen Rodriguez Blazquez, Spain 406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayela Rodriguez Violante, Mexico 301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raymond Rosales, Philippines 601</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne Rosser, United Kingdom 305</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janet Rucker, USA 701</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tabish Saifee, United Kingdom 405</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veronica Santini, USA 504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rachel Saunders-Pullman, USA 403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Schlossmacher, Canada 302</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeremy Schmahmann, USA 317</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susanne Schneider, Germany 403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anette Schrag, United Kingdom 406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ali Shalash, Egypt 406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hufang Shang, People’s Republic of China 609</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathleen Shannon, USA 601</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hitoshi Shimada, Japan 313</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Siderowf, USA 901</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellen Sidransky, USA 307</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura Silveira-Moriyama, Brazil 318</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kristina Simonyan, USA 311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolfgang Singer, USA 315</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Sommerauer, Denmark 313</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meredith Spindler, USA 501</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henning Stahlberg, Switzerland 205</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Stamelou, Greece 102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Stanslaski, USA 902</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Stern, USA 101</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## FACULTY LISTING

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giovanni Stevanin</td>
<td>France</td>
<td>606</td>
</tr>
<tr>
<td>A. Jon Stoessl</td>
<td>Canada</td>
<td>313</td>
</tr>
<tr>
<td>Julie Stout</td>
<td>Australia</td>
<td>305</td>
</tr>
<tr>
<td>Indu Subramanian</td>
<td>USA</td>
<td>316</td>
</tr>
<tr>
<td>Carolyn Sue</td>
<td>Australia</td>
<td>304</td>
</tr>
<tr>
<td>Per Svenningsson</td>
<td>Sweden</td>
<td>208</td>
</tr>
<tr>
<td>Pille Taba</td>
<td>Estonia</td>
<td>316</td>
</tr>
<tr>
<td>Jun Takahashi</td>
<td>Japan</td>
<td>604</td>
</tr>
<tr>
<td>Louis Tan</td>
<td>Singapore</td>
<td>202</td>
</tr>
<tr>
<td>Eng-King Tan</td>
<td>Singapore</td>
<td>205</td>
</tr>
<tr>
<td>Ai Huey Tan</td>
<td>Malaysia</td>
<td>406</td>
</tr>
<tr>
<td>Caroline Tanner</td>
<td>USA</td>
<td>314</td>
</tr>
<tr>
<td>Claudia Testa</td>
<td>USA</td>
<td>405</td>
</tr>
<tr>
<td>Michele Tinazzi</td>
<td>Italy</td>
<td>303</td>
</tr>
<tr>
<td>Stephen Tisch</td>
<td>Australia</td>
<td>704</td>
</tr>
<tr>
<td>Eduardo Tolosa</td>
<td>Spain</td>
<td>302, 402</td>
</tr>
<tr>
<td>Claudia Trenkwalder</td>
<td>Germany</td>
<td>201, 208, 309</td>
</tr>
<tr>
<td>Elina Tripoliti</td>
<td>United Kingdom</td>
<td>503</td>
</tr>
<tr>
<td>David Vaillancourt</td>
<td>USA</td>
<td>306</td>
</tr>
<tr>
<td>Enza Maria Valente</td>
<td>Italy</td>
<td>307</td>
</tr>
<tr>
<td>Bart Van De Warrenburg</td>
<td>Netherlands</td>
<td>401</td>
</tr>
<tr>
<td>Marie Vidailhet</td>
<td>France</td>
<td>104, 207</td>
</tr>
<tr>
<td>Hirohsa Watanabe</td>
<td>Japan</td>
<td>401</td>
</tr>
<tr>
<td>Jeff Waugh</td>
<td>USA</td>
<td>301</td>
</tr>
<tr>
<td>Gregor Wenning</td>
<td>Austria</td>
<td>315</td>
</tr>
<tr>
<td>Jennifer Whitwell</td>
<td>USA</td>
<td>605</td>
</tr>
<tr>
<td>Allison Willis</td>
<td>USA</td>
<td>607</td>
</tr>
<tr>
<td>Heather Wilson</td>
<td>United Kingdom</td>
<td>313</td>
</tr>
<tr>
<td>Yih-Ru Wu</td>
<td>Taiwan</td>
<td>206</td>
</tr>
<tr>
<td>Ruey-Meei Wu</td>
<td>Taiwan</td>
<td>314</td>
</tr>
<tr>
<td>Maria Xilouri</td>
<td>Greece</td>
<td>610</td>
</tr>
<tr>
<td>Michael Zech</td>
<td>Germany</td>
<td>311</td>
</tr>
<tr>
<td>Theresa Zesiewicz</td>
<td>USA</td>
<td>103</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

The MDS Virtual Congress 2021 wishes to acknowledge the following commercial supporters to date:

DIAMOND LEVEL:

ABBVIE

PLATINUM LEVEL:

ACADIA™  BIAL  MEDTRONIC

SILVER LEVEL:

IPSEN  Roche

BRONZE LEVEL:

Acorda Therapeutics  Neurocrine Biosciences  Teva Pharmaceuticals
Britannia Pharmaceuticals Ltd.  PD Neurotechnology Ltd.  UniQure
EVER Pharma  PPD  Voyager Therapeutics

MARQUEE SPONSORS:
ADD ON TO LIFE!

“I'M SO HAPPY! DAD'S RESPONDING BETTER TO MEDICATION AGAIN!”

A once-daily COMT inhibitor\(^1\) that provides a clinically relevant reduction in OFF-time\(^2\) with a generally favourable tolerability profile\(^3\)
